Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 9Withdrawn 2Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Colonic Neoplasms 2Tongue Neoplasms 1Melanoma 1Localized Resectable Adult Primary Liver Cancer 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 27Taxes 9Capecitabine 8Albumin-Bound Paclitaxel 6pembrolizumab 5Radiosurgery 5Oxaliplatin 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Specimen Handling 4Secretin 4Fluorouracil 4Drug Therapy 4Ascorbic Acid 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Cyclophosphamide 3Cisplatin 3Biopsy 3palbociclib 2methylnaltrexone 2folfirinox 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Neoplasms × Chemotherapy, Adjuvant × Clear all
NCT00253526 2015-04-28

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT00524069 2013-02-01

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Roswell Park Cancer Institute

Phase NA Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡